文献速递乳腺癌妇科肿瘤消化系统肿瘤

胚系PALB2致病变异与癌症风险:524个家庭国际研究

Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.
PubMed 文献 · J Clin Oncol · 2019-12-16

该研究分析21个国家524个携带PALB2致病变异家庭,采用复杂分离分析估计年龄特异性相对风险和绝对风险。结果显示PALB2变异与女性乳腺癌、卵巢癌、胰腺癌和男性乳腺癌风险显著相关,至80岁女性乳腺癌绝对风险为53%。

要点

  • PALB2致病变异携带者女性乳腺癌风险显著升高,相对风险为7.18。
  • PALB2变异还与卵巢癌、胰腺癌和男性乳腺癌风险相关。
  • 未发现前列腺癌或结直肠癌风险增加。

核心结论

  • PALB2是主要乳腺癌易感基因,并与卵巢癌、胰腺癌和男性乳腺癌风险显著相关。

研究设计与样本

  • 分析21个国家524个携带PALB2致病变异家庭,采用复杂分离分析估计相对风险和绝对风险。

主要发现

  • 女性乳腺癌相对风险为7.18(95% CI 5.82-8.85,P=6.5×10-76)。
  • 卵巢癌相对风险为2.91(95% CI 1.40-6.04,P=4.1×10-3)。
  • 胰腺癌相对风险为2.37(95% CI 1.24-4.50,P=8.7×10-3)。
  • 男性乳腺癌相对风险为7.34(95% CI 1.28-42.18,P=2.6×10-2)。
  • 未发现前列腺癌或结直肠癌风险增加。

关键数值与推荐

  • 至80岁女性乳腺癌绝对风险为53%(95% CI 44%-63%)。
  • 至80岁卵巢癌绝对风险为5%(95% CI 2%-10%)。
  • 至80岁胰腺癌绝对风险女性为1%-4%、男性为2%-5%(95% CI)。
  • 至80岁男性乳腺癌绝对风险为1%(95% CI 0.2%-5%)。

临床怎么用

  • 可将PALB2纳入风险预测模型,优化携带者癌症风险管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To estimate age-specific relative and absolute cancer risks of breast cancer and to estimate risks of ovarian, pancreatic, male breast, prostate, and colorectal cancers associated with germline PALB2 pathogenic variants (PVs) because these risks have not been extensively characterized. METHODS: We analyzed data from 524 families with PALB2 PVs from 21 countries. Complex segregation analysis was used to estimate relative risks (RRs; relative to country-specific population incidences) and absolute risks of cancers. The models allowed for residual familial aggregation of breast and ovarian cancer and were adjusted for the family-specific ascertainment schemes. RESULTS: We found associations between PALB2 PVs and risk of female breast cancer (RR, 7.18; 95% CI, 5.82 to 8.85; P = 6.5 × 10-76), ovarian cancer (RR, 2.91; 95% CI, 1.40 to 6.04; P = 4.1 × 10-3), pancreatic cancer (RR, 2.37; 95% CI, 1.24 to 4.50; P = 8.7 × 10-3), and male breast cancer (RR, 7.34; 95% CI, 1.28 to 42.18; P = 2.6 × 10-2). There was no evidence for increased risks of prostate or colorectal cancer. The breast cancer RRs declined with age (P for trend = 2.0 × 10-3). After adjusting for family ascertainment, breast cancer risk estimates on the basis of multiple case families were similar to the estimates from families ascertained through population-based studies (P for difference = .41). On the basis of the combined data, the estimated risks to age 80 years were 53% (95% CI, 44% to 63%) for female breast cancer, 5% (95% CI, 2% to 10%) for ovarian cancer, 2%-3% (95% CI females, 1% to 4%; 95% CI males, 2% to 5%) for pancreatic cancer, and 1% (95% CI, 0.2% to 5%) for male breast cancer. CONCLUSION: These results confirm PALB2 as a major breast cancer susceptibility gene and establish substantial associations between germline PALB2 PVs and ovarian, pancreatic, and male breast cancers. These findings will facilitate incorporation of PALB2 into risk prediction models and optimize the clinical cancer risk management of PALB2 PV carriers.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Yang X, Leslie G, Doroszuk A, et al. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. J Clin Oncol. 2019. PMID: 31841383. doi:10.1200/JCO.19.01907

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。